Physician profile
George Spivack
NPI 1720017049
$10,055.89
in general payments reported to CMS, 2019-2025
40 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $727 · 2021: $1,668 · 2022: $1,510 · 2023: $1,835 · 2024: $1,797 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,673.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,097.31 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,088.19 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $852.06 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $679.81 | 2019-2025 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $555.08 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $511.93 | 2019-2025 | |
| Esperion Therapeutics, INC. | $483.13 | 2021-2025 | Nexletol |
| Amgen INC. | $477.80 | 2019-2025 | Repatha |
| Amarin Pharma, INC. | $461.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $403.62 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $315.89 | 2019-2025 | Onpattro |
| Scpharmaceuticals INC. | $314.33 | 2023-2025 | |
| Novo Nordisk INC | $307.28 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Actelion Pharmaceuticals US, INC. | $238.05 | 2019-2025 | Opsumit, Uptravi |
| Heartflow, INC. | $228.41 | 2022-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Spivack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.